United Therapeutics (UTHR) acquires Thymmune Therapeutics for $140M upfront, with up to $160M in milestone-based payments.
United Therapeutics Corp. (NASDAQ:UTHR) said Thursday it has acquired privately held Thymmune Therapeutics.
Thymmune is a preclinical biotechnology company developing regenerative thymic cell therapies designed to restore immune function and improve transplant outcomes.
Read Next
News
FDA Approval Positions United Therapeutics To Broaden Access To Donor Lungs
United Therapeutics Corporation Acquires Thymmune Therapeutics
United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion
Zymeworks to acquire troubled biotech Theravance in $929M deal
Vertex's sickle cell therapy approved for kids; United Therapeutics buys startup
Zymeworks acquires struggling Theravance for $929M
Theravance, after clinical setbacks, agrees to $929M buyout
BridgeBio gets funding for drug launch; United buys into cell therapy
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
Orca-T Approved to Prevent GVHD After Stem Cell Transplant for Blood Cancers
United Therapeutics Corporation Acquires Thymmune Therapeutics
United Therapeutics received FDA approval for LungFX, a device designed to expand donor lung use in transplantation.
United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion
Expanding platform with next-generation VHH, lambda common light chain, and specialized long-CDR3 technologies MOUNTAIN VIEW, CA…
Zymeworks to acquire Theravance Biopharma for $929M, gaining rights to COPD drug Yupelri's US profit share and ex-US royalties…
Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expanding its portfolio.
